使用他汀類藥物與新發轉移性前列腺癌病人預後的相關性
陳子双1、劉惠瑛1、張殷綸1、莊燿吉1、陳彥達1、蘇祐立2、黃俊杰3、吳彥廷1、
王弘仁1、羅浩倫1
1高雄長庚紀念醫院 泌尿科 ; 2高雄長庚紀念醫院 血液腫瘤科 ; 3高雄長庚紀念醫院 放射腫瘤科
Association between statin use and clinical outcomes in patients with de novo metastatic prostate cancer: A propensity score-weighted analysis
Tzu Shuang Chen1, Hui Ying Liu1, Yin Lun Chang1, Yao Chi Chuang1, Yen Ta Chen1, Yu Li Su2,
Chun Chieh Huang3, Yen-Ting Wu1, Hung Jen Wang1, Hao Lun Luo1
1Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
2Department of Hematology and Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
3Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
Purpose: Several studies have reported conflicting results regarding the benefit of statins in prostate cancer. We aimed to evaluate the association between statin use and clinical outcomes in men with de novo metastatic prostate cancer in Taiwan.
Materials and Methods: Patients diagnosed de novo metastatic prostate cancer were identified from Chang Gung Research Database between 2007 and 2020. We use the inverse probability of treatment weighting (IPTW) method to reduce the confounding bias. The clinical outcomes were estimated by the IPTW-adjusted Kaplan-Meier curves. Multivariate Cox proportional hazard regression was used to assess the association between mortality and clinical factors.
Results: The study included 1716 statin users and 276 nonusers. Patients who used statins after prostate cancer diagnosis had longer average survival times compared with nonusers (4.3 years and 3.9 years, respectively; p=0.001). Multivariable Cox proportional hazards regression analysis after IPTW found that statin users were significantly associated with better overall survival (HR= 0.60, p <0.001).
Conclusions: In our study, statin use after de novo metastatic prostate cancer diagnosis improves survival outcome. Further large and long-term studies are needed to investigate the biologic effects of statins in men with prostate cancer.